Published in Am Heart J on February 23, 2009
Niacin Plus Statin to Prevent Vascular Events | NCT00120289
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE) | NCT00461630
Carotid Atherosclerosis Regression at Magnetic Resonance Assessment. | NCT00307307
Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol (2015) 1.11
Increasing spatial resolution of 3T MRI scanning improves reproducibility of carotid arterial wall dimension measurements. MAGMA (2013) 0.89
Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther (2013) 0.87
Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol (2012) 0.86
Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir. Arterioscler Thromb Vasc Biol (2009) 0.86
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Lipids Health Dis (2010) 0.81
High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis (2016) 0.80
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vasc Health Risk Manag (2010) 0.79
Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects. Arterioscler Thromb Vasc Biol (2015) 0.78
Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct? Curr Atheroscler Rep (2015) 0.75
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 9.97
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med (2006) 4.91
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation (2006) 4.25
Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation (2006) 3.49
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med (2003) 2.97
Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA (1996) 2.89
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet (2007) 2.65
Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol (2005) 2.61
Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem (2003) 2.52
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med (2007) 2.41
Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol (2002) 2.38
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.29
Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol (2001) 2.14
The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol (2007) 1.70
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin (2006) 1.53
C-reactive protein and coronary artery calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA). Arterioscler Thromb Vasc Biol (2003) 1.43
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol (2005) 1.35
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res (2004) 1.31
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol (2008) 1.25
Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res (1991) 1.21
High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol (2003) 1.13
Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol (2005) 1.13
Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol (2005) 1.12
Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol (2003) 1.04
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol (2001) 1.03
Relationship between the concentration and antiatherogenic activity of high-density lipoproteins. Curr Opin Lipidol (2006) 1.02
Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol (2003) 0.95
Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol (1991) 0.95
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol (2003) 0.94
EFFECT OF NICOTINIC ACID ON THE TURNOVER RATE AND OXIDATION OF THE FREE FATTY ACIDS OF PLASMA IN MAN DURING EXERCISE. Metabolism (1963) 0.93
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol (2003) 0.91
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol (2003) 0.86
Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol (2001) 0.85
Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol (1998) 0.84
Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol (1994) 0.81
The effects of niacin on lipoprotein subclass distribution. Prev Cardiol (2004) 0.80
Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations. Atherosclerosis (1988) 0.80
Current Drug Options for Raising HDL Cholesterol. Curr Treat Options Cardiovasc Med (2005) 0.77
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg (2006) 10.79
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet (2010) 5.31
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet (2013) 3.87
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med (2007) 3.70
Resistin is an inflammatory marker of atherosclerosis in humans. Circulation (2005) 3.52
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 3.49
Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation (2005) 3.25
Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation (2003) 3.24
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet (2011) 3.07
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Inflammation impairs reverse cholesterol transport in vivo. Circulation (2009) 2.86
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
Amplitude-modulated continuous arterial spin-labeling 3.0-T perfusion MR imaging with a single coil: feasibility study. Radiology (2005) 2.69
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med (2004) 2.51
Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab (2007) 2.48
Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol (2008) 2.42
Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA (2003) 2.32
Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes (2009) 2.27
Noninvasive measurement of cerebral blood flow and blood oxygenation using near-infrared and diffuse correlation spectroscopies in critically brain-injured adults. Neurocrit Care (2010) 2.26
Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis (2011) 2.25
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet (2012) 2.17
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet (2011) 1.92
Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost (2003) 1.91
CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol (2007) 1.87
Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci U S A (2010) 1.85
Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest (2009) 1.83
Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet (2010) 1.79
Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol (2005) 1.76
Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes. Diabetes Care (2009) 1.75
Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation (2002) 1.72
Association of the vitamin D metabolism gene CYP24A1 with coronary artery calcification. Arterioscler Thromb Vasc Biol (2010) 1.69
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int (2013) 1.66
Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr (2006) 1.65
A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet (2011) 1.63
Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation (2004) 1.62
Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet (2011) 1.60
Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. J Biol Chem (2009) 1.60
A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial. J Transl Med (2012) 1.59
Utility and barriers to performance of the ankle-brachial index in primary care practice. Vasc Med (2004) 1.57
Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab (2004) 1.55
A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock. Am J Respir Crit Care Med (2014) 1.53
Adipokines, insulin resistance, and coronary artery calcification. J Am Coll Cardiol (2008) 1.53
Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med (2005) 1.52
Overlap between common genetic polymorphisms underpinning kidney traits and cardiovascular disease phenotypes: the CKDGen consortium. Am J Kidney Dis (2013) 1.52
Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke (2013) 1.51
Genome-wide association study for circulating tissue plasminogen activator levels and functional follow-up implicates endothelial STXBP5 and STX2. Arterioscler Thromb Vasc Biol (2014) 1.45
Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes (2011) 1.44
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol (2005) 1.43
Claudication: exercise vs endoluminal revascularization (CLEVER) study update. J Vasc Surg (2009) 1.43
C-reactive protein and coronary artery calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA). Arterioscler Thromb Vasc Biol (2003) 1.43
Computed tomography-defined abdominal adiposity is associated with acute kidney injury in critically ill trauma patients*. Crit Care Med (2014) 1.41
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med (2006) 1.40
Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach. Atherosclerosis (2004) 1.40
The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol (2008) 1.36
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol (2005) 1.35
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet (2012) 1.35
Gene profiling of human adipose tissue during evoked inflammation in vivo. Diabetes (2009) 1.34
A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum Mol Genet (2011) 1.34
Intraaxial brain masses: MR imaging-based diagnostic strategy--initial experience. Radiology (2007) 1.33
Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. Proc Natl Acad Sci U S A (2011) 1.33
Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis (2012) 1.29
Achieving quality in cardiovascular imaging: proceedings from the American College of Cardiology-Duke University Medical Center Think Tank on Quality in Cardiovascular Imaging. J Am Coll Cardiol (2006) 1.29
Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet (2013) 1.27
Dense genotyping of candidate gene loci identifies variants associated with high-density lipoprotein cholesterol. Circ Cardiovasc Genet (2011) 1.27